Overall market sentiment has been high on Zosano Pharma Corp (ZSAN) stock lately. ZSAN receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With ZSAN Stock Today?
Zosano Pharma Corp (ZSAN) stock is lower by -5.92% while the S&P 500 has gained 0.21% as of 10:44 AM on Friday, May 28. ZSAN is lower by -$0.05 from the previous closing price of $0.86 on volume of 1,964,000 shares. Over the past year the S&P 500 is up 38.65% while ZSAN is lower by -22.12%. ZSAN lost -$0.41 per share in the over the last 12 months.
More About Zosano Pharma Corp
Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.